ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Targeting One Specific Protein Can Double PFS; Triple Overall Survival

May 27, 2011

RFA: Native American Women’s Cancer Initiative

July 9, 1993

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006

Provenge Prolonged Prostate Cancer Survival By Seven Months, Study Finds

September 26, 2003

In Brief: Hutchinson Awarded $8 Million Grant For Pancreatic, Colorectal Cancer Studies

September 18, 1998

Cancer Death Rate Declines, Clark Tells Science Writers

April 8, 1977